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Patientswithfulminanttype1diabetesalmostcompletelylackC-peptideevensoonaftertheonsetofthedisease,andthedeﬁciency
continuesfortherestoftheirlife.Thus,fulminanttype1diabetescouldserveasagoodmodelofnaturetoexplorethephysiological
role of C-peptide. For example, patients with fulminant type 1 diabetes have diabetic chronic complications more frequently than
those with classical autoimmune type 1 diabetes 5 years after the onset of diabetes, and the higher prevalence could be partly
attributable to the complete lack of C-peptide in fulminant type 1 diabetes.
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Type 1 diabetes mellitus is characterized by an insulin deﬁ-
ciency resulting from the destruction of pancreatic β-cells.
Recently, a novel subtype of type 1 diabetes has been
recorded and referred to as fulminant type 1 diabetes, which
accounts for approximately 20% of Japanese ketosis-onset
type 1 diabetes [1, 2]. Fulminant type 1 diabetes has the
following clinical characteristics: duration of hyperglycemic
symptoms is 4 days on average; a high prevalence of pre-
ceding common cold-like and gastrointestinal symptoms;
a near-normal level of glycated hemoglobin in spite of
very high plasma glucose levels associated with ketoacidosis,
sometimes related to pregnancy; and increased serum pan-
creatic enzyme levels, absent C-peptide levels (fasting serum
C-peptide < 0.10nmol/L or stimulated serum C-peptide <
0.17 nmol/L soon after the disease onset), but virtually no
detectable autoantibodies against constituents of pancreatic
β-cells. The process of β-cell destruction is extremely rapid.
Of note, in contrast to autoimmune type 1A diabetes, the
deﬁciency of insulin secretory capacity has already become
almost complete even at onset of diabetes, and the capacity
rarely recovers after the onset. The patients are treated with
recombinant human insulin, but C-peptide is not replaced.
Thus, fulminant type 1 diabetes could serve as a good model
of nature to explore the physiological role of C-peptide.
We conducted a nationwide survey in Japan to assess
the development of microvascular complications in fulmi-
nant type 1 diabetes of 5 years’ duration in comparison with
a c u t e - o n s e ta u t o i m m u n et y p e1 Ad i a b e t e s[ 3, 4]. Five-year
cumulative incidence of microangiopathy was 24.4% in ful-
minant type 1 diabetes and 2.6% in type 1A diabetes. The
cumulative incidence of each microangiopathy was signif-
icantly higher in fulminant type 1 diabetes than in type
1A diabetes; retinopathy was 9.8% versus 0% (P = .014),
nephropathy 12.2% versus 2.6% (P = .015), and neuropa-
thy 12.2% versus 1.3% (P = .010), respectively. Also, logis-
tic regression analysis showed that decreased C-peptide se-
cretion was a risk for retinopathy (β = 0.29;P = .04,β =
−0.27;P<. 05,resp.)andneuropathy(β = 0.39,P = .01;β =
−0.25,P<. 05, resp.). Mean HbA1c levels were similar in ful-
minant and type 1A diabetes group during the follow-up pe-
riods. However, mean M-value, mean insulin dosages, and
the frequency of severe hypoglycemic episodes were signif-
icantly higher, and mean postprandial C-peptide level was
signiﬁcantly lower in fulminant type 1 diabetes than in type
1A diabetes (0.08 ± 0.04 versus 0.24 ± 0.15 nmol/L, P =
.0007). These results suggest that depleted and irreversible
insulin production is associated with unstable blood glucose
control, as indicated by increased M-value, and thereby high
incidence of diabetic microvascular complications in fulmi-
nant type 1 diabetic patients. Here, the following interpre-
tation is possible: lack of C-peptide itself (Figure 1), in ad-
dition to instability of glucose levels, might play a role in
the development of microangiopathy in fulminant type 1
diabetic patients. Indeed, the mean postprandial C-peptide2 Experimental Diabetes Research
5 4 3 2 1 0
Duration (years)
0
0.04
0.08
0.12
0.16
0.2
S
e
r
u
m
C
-
p
e
p
t
i
d
e
(
n
m
o
l
/
L
)
Figure 1: Serum C-peptide levels for 5 years from fulminant dia-
betes onset. Adapted from [4].
levels were almost undetectable even at the onset of diabetes
(0.06±0.03nmol/L) and throughout the 5-year study in ful-
minant diabetic patients, while they were detectable at and
decreased gradually after the onset in classical type 1A dia-
betes [5, 6].
C-peptidehasbeenconsideredtobeagoodmarkerofin-
sulinsecretionandhasnobiologicalactivityofitsown.How-
ever, over the last decade, several reports have suggested that
C-peptide exerts a number of physiological eﬀects, which are
probably mediated by stimulation of Na+,K +-ATPase, and
endothelial nitric oxide synthetase activities in several tissues
[7]. At the early stage of type 1 diabetes, C-peptide replace-
ment was shown to result in diminished urinary albumin
excretion rate and ameliorates nerve dysfunction [8]. In the
light of these data, fulminant type 1 diabetes could provide
an ideal setting to explore whether C-peptide administration
beneﬁts patients with diabetes in reducing microangiopathy.
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